

BANGKOK CHAIN HOSPITAL

THAILAND / HEALTH CARE SERVICES

BCH TB

BUY
 UNCHANGED

From soft patch to rebound

- Expect 1Q25 profit to drop by 3% y-y to THB310m due to slowdown of Middle East patient revenue.
- International patient revenue should shift its trend from declining to stabilizing from 2Q25 onward due to a normalized base.
- Maintain BUY with a new DCF-TP of THB20/shr.

TARGET PRICE	THB20.00
CLOSE	THB14.40
UP/DOWNSIDE	+38.9%
PRIOR TP	THB20.00
CHANGE IN TP	UNCHANGED
TP vs CONSENSUS	+8.3%

KEY STOCK DATA

YE Dec (THB m)	2024	2025E	2026E	2027E
Revenue	11,725	12,660	13,671	14,458
Net profit	1,282	1,587	1,784	1,953
EPS (THB)	0.51	0.64	0.72	0.78
vs Consensus (%)	-	0.9	(0.6)	2.4
EBITDA	2,602	3,152	3,464	3,736
Recurring net profit	1,200	1,587	1,784	1,953
Core EPS (THB)	0.48	0.64	0.72	0.78
Chg. In EPS est. (%)	nm	0.0	0.0	nm
EPS growth (%)	(14.7)	32.2	12.4	9.5
Core P/E (x)	29.9	22.6	20.1	18.4
Dividend yield (%)	3.5	2.8	2.8	3.0
EV/EBITDA (x)	14.0	11.3	10.0	9.0
Price/book (x)	2.8	2.7	2.5	2.4
Net debt/Equity (%)	(3.5)	(9.1)	(15.5)	(21.7)
ROE (%)	9.4	12.0	12.8	13.2

Middle East patients to drag 1Q25 revenue growth

We expect 1Q25 revenue to grow by 2% y-y. General patient revenue should grow by 2-3% y-y, driven by Thai patient revenue, which should more than offset a decrease in international patient revenue following the absence of Kuwaiti patient revenue and the Ramadan period in March. This should be the first y-y increase in general patient revenue since 1Q24. Meanwhile, SSO revenue should grow by 1-2% y-y due to a slight increase in SSO registered members. Overall, we expect the 1Q25 EBITDA margin to be relatively flat y-y at 24%. This should lead 1Q25 core profit to slightly decline by 3% y-y THB310m.

Earnings growth to resume in 2Q25


We expect core profit to bounce back and grow again in 2Q25 due to the low base in 2Q24 when BCH booked a THB81m SSO revenue reversal from a cut to high-cost care payments. In addition, Middle East (ME) patient revenue has declined from THB200-300m/quarter (9% revenue contribution) in 2023 to cTHB100m in 2Q-4Q24 (3% revenue contribution). Thus, we believe ME patient revenue will reverse its downward trend and start to normalize from 2Q25 onward. Therefore, general patient revenue should resume its normal growth rate of c5% y-y.

Expect core profit to jump by 29% y-y to THB1.6b in 2025

We expect 2025 profit to jump 29% y-y to THB1.6b in the absence of the SSO revenue reversal totaling cTHB241m (THB81m in 2Q24 and cTHB160m in 4Q24), since the SSO changed its payment scheme to be fixed at THB12,000/RW, effective Jan-25. In addition, the loss from three new hospitals should reduce from THB204m in 2024 to THB80-100m in 2025, driven mainly by KIH Aranyaprathet, which has seen a strong patient volume flow since the beginning of this year.

Expect operations to hit the bottom in 1Q25

We maintain our core profit forecast. BCH trades at an attractive valuation of 23x 2025E P/E (vs 5-year average of 26x). We believe operations are likely to hit the bottom in 1Q25, and earnings growth should resume in 2Q25. The upside includes the PPP project for Pluak Daeng 2 hospital, in which BCH plans to participate in the bidding. The result should be announced by 3Q25.



Share price performance	1 Month	3 Month	12 Month
Absolute (%)	2.9	(2.7)	(32.7)
Relative to country (%)	4.3	12.9	(21.1)
Mkt cap (USD m)	1,067		
3m avg. daily turnover (USD m)	2.5		
Free float (%)	44		
Major shareholder	Chalerm Hamphanich (33%)		
12m high/low (THB)	21.60/13.40		
Issued shares (m)	2,493.75		

Sources: Bloomberg consensus; FSSIA estimates



Teerapol Udomvej, CFA

Fundamental Investment Analyst on Securities; License no. 080523
 teerapol.udo@fssia.com, +66 2646 9969

Investment thesis

BCH is a leading service provider under the Social Security Office (SSO) scheme. BCH received a large SSO quota of 314k in 2024. This should lead to more registered members numbering around 100k for BCH over 2024-26.

In 2020-21, BCH opened three new hospitals, which continue to share a loss. However, their operations are improving, and all should turn profitable by 2025-26, leading to better EBITDA and an improved NPM.

Revenue from international patients slowed down in 2024 due to a decline in Kuwaiti patient revenue. We expect revenue growth to resume in 2025, driven by CLMV patients, with the scope of an upside if the Kuwaiti government resumes patient referrals to Thailand.

Company profile

The company operates its business as a group, providing healthcare services for both cash patients and patients under the social security scheme.


www.bangkokchainhospital.com

Principal activities (revenue, 2024)

Cash patient revenue - 67.6 %

SSO patient revenue - 33.2 %

NHSO patient revenue - (0.8) %



Source: Bangkok Chain Hospital


Major shareholders

Chalerm Harnphanich - 32.6 %

Thai NVDR - 7.3 %

Somporn Harnphanich - 6.6 %

Others - 53.5 %



Source: Bangkok Chain Hospital

Catalysts

Key potential growth drivers include 1) more SSO-registered members; 2) increased demand from medical tourists; and 3) an improved EBITDA margin, led by new hospitals.

Risks to our call

Downside risks to our DCF-based target price include 1) a slowdown in international patients due to economic concerns, political protests or floods; 2) regulatory risks from drug prices and medical bill controls; and 3) SSO provision expenses following a limited SSO budget.

Event calendar

Date	Event
May 2025	1Q25 results announcement

Key assumptions


	2025E	2026E	2027E
	(%)	(%)	(%)
SSO volume growth	3	5	3
SSO revenue / patient growth	5	4	4
OPD volume growth	4	4	2
OPD revenue / patient growth	2	2	3
IPD volume growth	4	4	2
IPD revenue / patient growth	4	4	3

Source: FSSIA estimates


Earnings sensitivity

- For every 1% increase in patient volume, we project 2025 earnings would rise by 2%, and vice versa, all else being equal.
- For every 1% increase in EBITDA margin, we project 2025 earnings would rise by 5%, and vice versa, all else being equal.


Source: FSSIA estimates

Exhibit 1: Middle East (ME) patient revenue


Sources: BCH; FSSIA estimates

Exhibit 2: Non-ME international patient revenue


Sources: BCH; FSSIA estimates

Exhibit 3: General patient revenue


Sources: BCH; FSSIA estimates

Exhibit 4: SSO revenue, quarterly

Sources: BCH; FSSIA estimates

Exhibit 5: EBITDA margin

Sources: BCH; FSSIA estimates

Exhibit 6: Core profit


Sources: BCH; FSSIA estimates

Exhibit 7: BCH – 1Q25 results preview

	1Q24	2Q24	3Q24	4Q24	1Q25E	----- Change -----		2024	2025E	Chg.
	(THB m)	(THB m)	(THB m)	(THB m)	(THB m)	(q-q %)	(y-y %)	(THB m)	(THB m)	(y-y %)
Sales	2,844	2,857	3,261	2,763	2,915	6	2	11,725	12,660	8
COGS (incl. depreciation)	(2,044)	(2,112)	(2,238)	(2,133)	(2,104)	(1)	3	(8,527)	(8,936)	5
Gross profit	801	744	1,023	630	812	29	1	3,199	3,724	16
SG&A	(376)	(388)	(417)	(414)	(395)	(5)	5	(1,595)	(1,646)	3
Operating profit	425	356	607	216	417	93	(2)	1,604	2,079	30
Net other income	23	28	24	45	24	(47)	5	121	120	(1)
Interest expense	(11)	(13)	(15)	(15)	(15)	0	37	(55)	(42)	(23)
Pretax profit	437	372	615	246	426	73	(2)	1,670	2,157	29
Income Tax	(87)	(70)	(122)	(48)	(85)	79	(2)	(346)	(431)	25
Associates	0	(0)	(0)	(0)	0			(1)	(1)	0
Minority interest	(31)	(25)	(40)	(27)	(31)	16	0	(123)	(138)	12
Core profit	319	277	453	171	310	81	(3)	1,200	1,587	32
Extraordinaries, GW & FX	0	0	0	62						
Reported net profit	319	277	453	233	310	33	(3)	1,200	1,587	32
Outstanding shares (m)	2,494	2,494	2,494	2,494	2,494	0	0	2,494	2,494	0
Core EPS (THB)	0.13	0.11	0.18	0.09	0.12	33	(3)	0.48	0.64	32
EPS (THB)	0.13	0.11	0.18	0.09	0.12	33	(3)	0.48	0.64	32
COGS (excl. depreciation)	1,803	1,871	1,987	1,868	1,836	(2)	2	7,529	7,862	4
Depreciation	240	242	251	265	268	1	11	998	1,074	8
EBITDA	688	626	882	527	709	35	3	2,722	3,272	20
Key ratios	(%)	(%)	(%)	(%)	(%)	(ppt)	(ppt)	(%)	(%)	(ppt)
Gross margin	28	26	31	23	28	5	(0)	27	29	2
SG&A/Revenue	13	14	13	15	14	(1)	0	14	13	(1)
EBITDA margin	24	22	27	19	24	5	0	22	25	3
Net profit margin	11	10	14	8	11	2	(1)	10	13	2
Operating stats	(y-y %)	(y-y %)	(y-y %)	(y-y %)						
Cash-OPD revenue growth	14	9	11	0						
Cash-OPD volume growth	10	(8)	(3)	(11)						
Cash-OPD revenue per head growth	3	18	14	16						
Cash-IPD revenue growth	(1)	(13)	(14)	(15)						
Cash-IPD volume growth	5	(1)	(11)	(16)						
Cash-IPD revenue per head growth	(6)	(12)	(4)	2						
SSO revenue growth	9	0	12	(16)						
SSO registered member ('000)	1,015	1,017	1,021	1,031						
SSO registered member growth	0	0	1	2						
SSO revenue per head growth	8	(0)	11	(17)						


Sources: BCH; FSSIA estimates

Exhibit 8: Historical P/E band



Sources: Bloomberg; FSSIA estimates

Exhibit 9: Historical P/BV band



Sources: Bloomberg; FSSIA estimates

Exhibit 10: Peer comparisons as of 28 Apr 2025

Company	BBG	Rec	Share price			Market Cap	PE		ROE		PBV		EV/ EBITDA	
			Current	Target	Upside		25E	26E	25E	26E	25E	26E	25E	26E
			(LCY)	(LCY)	(%)	(USD m)	(x)	(x)	(%)	(%)	(x)	(x)	(x)	(x)
Thailand														
Bangkok Dusit Med Service	BDMS TB	BUY	23.10	36.50	58.0	10,907	20.8	19.0	17.1	17.7	3.5	3.3	13.0	11.8
Bumrungrad Hospital	BH TB	BUY	158.50	220.00	38.8	3,744	16.0	15.6	26.8	24.4	4.0	3.6	10.5	9.7
Bangkok Chain Hospital	BCH TB	BUY	14.40	20.00	38.9	1,067	22.6	20.1	12.0	12.8	2.7	2.5	11.3	10.0
Chularat Hospital	CHG TB	BUY	1.78	2.60	46.1	582	17.9	15.5	13.9	15.1	2.4	2.3	9.8	8.6
Patangsit Healthcare Group	PHG TB	BUY	13.90	21.00	51.1	124	12.7	11.1	15.1	16.0	1.9	1.7	6.0	5.3
Praram 9 Hospital	PR9 TB	BUY	24.10	30.00	24.5	563	23.2	20.9	14.3	14.6	3.2	2.9	13.0	11.3
Thonburi Healthcare Group	THG TB	HOLD	9.80	40.00	308.2	247	10.4	8.1	7.6	9.4	0.8	0.7	7.5	6.2
Ramkhamhaeng Hospital	RAM TB	BUY	18.10	44.00	143.1	645	11.0	9.6	10.0	10.8	1.1	1.0	14.8	12.7
Srivichai Vejvivat	VIH TB	BUY	7.15	14.00	95.8	129	11.8	12.8	10.4	8.9	1.2	1.1	5.8	7.2
Rajthanee Hospital	RJH TB	n/a	13.20	n/a	n/a	116	9.4	9.5	20.7	20.0	1.8	1.7	8.0	7.3
Ekachai Medical Care	EKH TB	n/a	6.15	n/a	n/a	153	15.0	14.1	11.5	11.2	1.9	1.8	9.0	8.8
Thailand average						18,277	15.5	14.2	14.5	14.6	2.2	2.1	9.9	9.0
Regional														
Ramsay Health Care	RHC AU	n/a	33.69	n/a	n/a	4,990	26.7	21.4	5.2	7.2	1.6	1.5	9.0	8.4
Ihh Healthcare Bhd	IHH SP	n/a	2.05	n/a	n/a	13,959	30.8	27.3	6.6	7.2	1.9	1.8	12.6	11.5
Ryman Healthcare	RYM NZ	n/a	2.34	n/a	n/a	1,419	39.0	19.7	0.9	2.1	0.4	0.4	32.3	31.8
Apollo Hospitals Enterprise	APHS IN	n/a	7,045	n/a	n/a	11,803	70.1	52.8	18.9	20.8	12.5	10.3	34.7	28.2
Kpj Healthcare Berhad	KPJ MK	n/a	2.73	n/a	n/a	2,868	31.9	28.1	14.6	15.3	4.6	4.3	15.0	13.9
Raffles Medical Group	RFMD SP	n/a	1.00	n/a	n/a	1,415	27.0	23.8	6.6	7.1	1.7	1.7	11.9	11.2
Mitra Keluarga Karyasehat	MIKA IJ	n/a	2,500	n/a	n/a	2,123	28.4	25.4	18.7	19.0	4.9	4.5	17.1	15.4
Aier Eye Hospital Group	300015 CH	n/a	13.00	n/a	n/a	16,691	29.1	25.2	18.0	18.1	5.0	4.4	17.3	15.4
Regional average						55,270	35.4	28.0	11.2	12.1	4.1	3.6	18.8	17.0
Overall average						73,547	23.9	20.0	13.1	13.6	3.0	2.7	13.6	12.4

Sources: Bloomberg; FSSIA estimates

Financial Statements

Bangkok Chain Hospital

Profit and Loss (THB m) Year Ending Dec	2023	2024	2025E	2026E	2027E
Revenue	11,729	11,725	12,660	13,671	14,458
Cost of goods sold	(8,116)	(8,527)	(8,936)	(9,581)	(10,064)
Gross profit	3,613	3,199	3,724	4,090	4,394
Other operating income	-	-	-	-	-
Operating costs	(1,755)	(1,595)	(1,646)	(1,750)	(1,836)
Operating EBITDA	2,802	2,602	3,152	3,464	3,736
Depreciation	(944)	(998)	(1,074)	(1,124)	(1,178)
Goodwill amortisation	-	-	-	-	-
Operating EBIT	1,859	1,604	2,079	2,340	2,558
Net financing costs	(77)	(41)	(33)	(37)	(30)
Associates	1	(1)	(1)	(1)	(1)
Recurring non-operating income	102	106	111	116	122
Non-recurring items	0	82	0	0	0
Profit before tax	1,883	1,752	2,156	2,419	2,650
Tax	(405)	(346)	(431)	(484)	(530)
Profit after tax	1,479	1,405	1,725	1,935	2,120
Minority interests	(73)	(123)	(138)	(151)	(167)
Preferred dividends	-	-	-	-	-
Other items	-	-	-	-	-
Reported net profit	1,406	1,282	1,587	1,784	1,953
Non-recurring items & goodwill (net)	0	(82)	0	0	0
Recurring net profit	1,406	1,200	1,587	1,784	1,953
Per share (THB)					
Recurring EPS *	0.56	0.48	0.64	0.72	0.78
Reported EPS	0.56	0.51	0.64	0.72	0.78
DPS	0.50	0.50	0.40	0.40	0.43
Diluted shares (used to calculate per share data)	2,494	2,494	2,494	2,494	2,494
Growth					
Revenue (%)	(37.7)	0.0	8.0	8.0	5.8
Operating EBITDA (%)	(44.6)	(7.2)	21.2	9.9	7.8
Operating EBIT (%)	(54.8)	(13.7)	29.6	12.6	9.3
Recurring EPS (%)	(53.7)	(14.7)	32.2	12.4	9.5
Reported EPS (%)	(53.7)	(8.8)	23.8	12.4	9.5
Operating performance					
Gross margin inc. depreciation (%)	30.8	27.3	29.4	29.9	30.4
Gross margin exc. depreciation (%)	38.9	35.8	37.9	38.1	38.5
Operating EBITDA margin (%)	23.9	22.2	24.9	25.3	25.8
Operating EBIT margin (%)	15.8	13.7	16.4	17.1	17.7
Net margin (%)	12.0	10.2	12.5	13.0	13.5
Effective tax rate (%)	21.5	20.7	20.0	20.0	20.0
Dividend payout on recurring profit (%)	88.7	103.8	62.9	55.9	54.8
Interest cover (X)	25.4	41.8	66.1	66.3	88.4
Inventory days	17.0	15.4	15.7	15.5	15.7
Debtor days	37.0	27.2	26.2	24.3	23.0
Creditor days	67.9	65.6	63.6	62.7	63.4
Operating ROIC (%)	10.9	9.9	12.9	14.8	16.5
ROIC (%)	10.9	10.0	12.8	14.6	16.2
ROE (%)	11.2	9.4	12.0	12.8	13.2
ROA (%)	8.2	7.7	9.9	10.5	10.9

* Pre-exceptional, pre-goodwill and fully diluted

Revenue by Division (THB m)	2023	2024	2025E	2026E	2027E
Cash patient revenue	7,976	7,930	8,484	9,079	9,538
SSO patient revenue	3,850	3,889	4,205	4,592	4,919
NHSO patient revenue	(97)	(93)	(30)	0	0

Sources: Bangkok Chain Hospital; FSSIA estimates

Financial Statements

Bangkok Chain Hospital

Cash Flow (THB m) Year Ending Dec	2023	2024	2025E	2026E	2027E
Recurring net profit	1,406	1,200	1,587	1,784	1,953
Depreciation	944	998	1,074	1,124	1,178
Associates & minorities	-	-	-	-	-
Other non-cash items	114	465	128	151	167
Change in working capital	1,563	253	25	59	41
Cash flow from operations	4,027	2,916	2,815	3,118	3,339
Capex - maintenance	(896)	(1,571)	(877)	(957)	(1,012)
Capex - new investment	-	-	-	-	-
Net acquisitions & disposals	4	(62)	0	0	0
Other investments (net)	-	-	-	-	-
Cash flow from investing	(892)	(1,633)	(877)	(957)	(1,012)
Dividends paid	(1,247)	(1,246)	(997)	(997)	(1,070)
Equity finance	0	0	0	0	0
Debt finance	(2,310)	(681)	0	0	0
Other financing cash flows	(32)	(160)	(87)	(91)	(92)
Cash flow from financing	(3,590)	(2,087)	(1,084)	(1,088)	(1,162)
Non-recurring cash flows	-	-	-	-	-
Other adjustments	0	0	0	0	0
Net other adjustments	0	0	0	0	0
Movement in cash	(455)	(803)	854	1,073	1,165
Free cash flow to firm (FCFF)	3,230.18	1,338.18	1,979.40	2,212.51	2,377.85
Free cash flow to equity (FCFE)	791.94	442.79	1,851.03	2,070.53	2,235.11
Per share (THB)					
FCFF per share	1.30	0.54	0.79	0.89	0.95
FCFE per share	0.32	0.18	0.74	0.83	0.90
Recurring cash flow per share	0.99	1.07	1.12	1.23	1.32
Balance Sheet (THB m) Year Ending Dec	2023	2024	2025E	2026E	2027E
Tangible fixed assets (gross)	20,884	23,120	24,006	24,963	25,975
Less: Accumulated depreciation	(8,639)	(10,287)	(11,361)	(12,485)	(13,663)
Tangible fixed assets (net)	12,244	12,834	12,646	12,479	12,313
Intangible fixed assets (net)	440	436	436	436	436
Long-term financial assets	-	-	-	-	-
Invest. in associates & subsidiaries	28	90	90	90	90
Cash & equivalents	2,185	1,382	2,236	3,309	4,473
A/C receivable	839	910	910	910	910
Inventories	306	331	345	372	390
Other current assets	1,513	1,150	1,242	1,341	1,418
Current assets	4,843	3,773	4,732	5,931	7,192
Other assets	176	243	243	243	243
Total assets	17,731	17,375	18,147	19,178	20,273
Common equity	12,594	12,955	13,545	14,331	15,214
Minorities etc.	1,110	1,072	1,123	1,183	1,258
Total shareholders' equity	13,704	14,027	14,668	15,515	16,472
Long term debt	1,497	324	324	324	324
Other long-term liabilities	187	203	203	203	203
Long-term liabilities	1,684	528	528	528	528
A/C payable	1,368	1,340	1,399	1,505	1,582
Short term debt	81	573	573	573	573
Other current liabilities	894	907	979	1,058	1,118
Current liabilities	2,342	2,820	2,952	3,136	3,273
Total liabilities and shareholders' equity	17,731	17,375	18,147	19,178	20,273
Net working capital	396	143	118	59	18
Invested capital	13,284	13,746	13,533	13,307	13,100
* Includes convertibles and preferred stock which is being treated as debt					
Per share (THB)					
Book value per share	5.05	5.20	5.43	5.75	6.10
Tangible book value per share	4.87	5.02	5.26	5.57	5.93
Financial strength					
Net debt/equity (%)	(4.4)	(3.5)	(9.1)	(15.5)	(21.7)
Net debt/total assets (%)	(3.4)	(2.8)	(7.4)	(12.6)	(17.6)
Current ratio (x)	2.1	1.3	1.6	1.9	2.2
CF interest cover (x)	11.3	11.8	56.9	56.9	74.8
Valuation	2023	2024	2025E	2026E	2027E
Recurring P/E (x) *	25.5	29.9	22.6	20.1	18.4
Recurring P/E @ target price (x) *	35.5	41.6	31.4	28.0	25.5
Reported P/E (x)	25.5	28.0	22.6	20.1	18.4
Dividend yield (%)	3.5	3.5	2.8	2.8	3.0
Price/book (x)	2.9	2.8	2.7	2.5	2.4
Price/tangible book (x)	3.0	2.9	2.7	2.6	2.4
EV/EBITDA (x) **	13.0	14.0	11.3	10.0	9.0
EV/EBITDA @ target price (x) **	18.0	19.4	15.8	14.0	12.7
EV/invested capital (x)	2.7	2.7	2.6	2.6	2.6
* Pre-exceptional, pre-goodwill and fully diluted ** EBITDA includes associate income and recurring non-operating income					

Sources: Bangkok Chain Hospital; FSSIA estimates

Bangkok Chain Hospital PCL (BCH TB)

FSSIA ESG rating


39.71 /100

Exhibit 11: FSSIA ESG score implication

Rating	Score	Implication
★★★★★	>79-100	Leading its industry peers in managing the most significant ESG risks which not only better cost efficiency but also lead to higher profitability.
★★★★☆	>59-79	A mixed track record of managing the most significant ESG risks and opportunities relative to industry peers.
★★★☆☆	>39-59	Relevant ESG materiality matrix has been constructively addressed, well-managed and incorporated into day-to-day operations, in which targets and achievements are evaluated annually.
★★☆☆☆	>19-39	Relevant ESG materiality matrix has been identified with key management in charge for progress to be followed up on and to provide intensive disclosure. Most targets are conventional and achievable.
★☆☆☆☆	1-19	The company has adopted the United Nations Sustainable Development Goals (UN SDGs), established sustainability management guidelines and fully complies with regulations or ESG suggested guidance from related organizations such as the SET and SEC.

Sources: FSSIA estimates

Exhibit 12: ESG – peer comparison

	FSSIA ESG score	Domestic ratings						Global ratings					Bloomberg		
		DJSI	SET ESG	SET ESG Rating	CG score	AGM level	Thai CAC	Morningstar ESG risk	ESG Book	MSCI	Moody's	Refinitiv	S&P Global	ESG score	Disclosure score
SET100	69.20	5.34	4.40	4.40	4.76	4.65	3.84	Medium	51.76	BBB	20.87	58.72	63.91	3.72	28.17
Coverage	67.12	5.11	4.15	4.17	4.83	4.71	3.53	Medium	52.04	BB	16.97	56.85	62.09	3.40	31.94
BCH	39.71	--	--	--	4.00	5.00	Certified	High	48.21	--	--	27.19	18.00	3.52	47.60
BDMS	74.00	Y	Y	Y	5.00	4.00	--	Medium	61.06	AA	34.00	59.83	72.00	3.45	58.92
BH	51.21	--	--	--	4.00	4.00	--	Medium	64.29	A	29.00	59.03	27.00	5.08	47.79
CHG	38.25	--	--	--	4.00	5.00	--	High	55.35	--	--	59.57	21.00	2.34	50.24
PR9	54.08	--	Y	Y	5.00	5.00	Certified	High	71.12	--	--	62.39	--	2.43	37.90
PRINC	18.00	--	--	--	4.00	4.00	Certified	--	--	--	--	--	--	--	--
RAM	11.75	--	--	--	3.00	--	--	High	--	--	--	--	--	--	--
THG	18.75	--	--	--	5.00	5.00	--	High	--	--	--	--	--	--	--
VIBHA	20.88	--	--	--	4.00	3.00	Declared	High	--	--	--	--	17.00	--	--

Sources: [SETTRADE.com](https://www.settrade.com); FSSIA's compilation

Exhibit 13: ESG score by Bloomberg

FY ending Dec 31	FY 2015	FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022
ESG financial materiality scores - ESG score	0.56	0.71	0.75	0.72	0.80	0.85	2.36	3.52
BESG environmental pillar score	0.00	0.00	0.00	0.00	0.38	0.38	2.96	4.63
BESG social pillar score	0.00	0.22	0.22	0.22	0.22	0.22	1.70	3.47
BESG governance pillar score	2.35	2.41	2.62	2.50	2.41	2.63	3.19	2.91
ESG disclosure score	18.06	19.81	19.81	19.81	20.08	20.08	31.27	47.60
Environmental disclosure score	0.00	0.42	0.42	0.42	1.24	1.24	20.57	46.18
Social disclosure score	3.17	10.52	10.52	10.52	10.52	10.52	18.53	41.96
Governance disclosure score	50.87	48.37	48.37	48.37	48.37	48.37	54.64	54.64
Environmental								
Emissions reduction initiatives	No	No	No	No	Yes	Yes	Yes	Yes
Climate change policy	No	No	No	No	No	No	Yes	Yes
Climate change opportunities discussed	No	No	No	No	No	No	No	No
Risks of climate change discussed	No	No	No	No	No	No	No	No
GHG scope 1	—	—	—	—	—	—	1	2
GHG scope 2 location-based	—	—	—	—	—	—	5	6
GHG Scope 3	—	—	—	—	—	—	—	—
Carbon per unit of production	—	—	—	—	—	—	—	—
Biodiversity policy	No	No	No	No	No	No	No	No
Energy efficiency policy	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Total energy consumption	—	—	—	—	—	—	10	12
Renewable energy use	—	—	—	—	—	—	—	—
Electricity used	—	—	—	—	—	—	10	12
Fuel used - natural gas	—	—	—	—	—	—	—	—

Sources: Bloomberg; FSSIA's compilation

Exhibit 14: ESG score by Bloomberg (cont.)

FY ending Dec 31	FY 2015	FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022
Fuel used - crude oil/diesel	No	No	No	No	No	No	No	No
Waste reduction policy	No	No	No	No	Yes	Yes	Yes	Yes
Hazardous waste	—	—	—	—	—	—	—	0
Total waste	—	—	—	—	—	—	—	0
Waste recycled	—	—	—	—	—	—	—	0
Waste sent to landfills	—	—	—	—	—	—	—	0
Environmental supply chain management	No	No	No	No	No	No	No	Yes
Water policy	No	No	No	No	No	No	Yes	Yes
Water consumption	—	—	—	—	—	—	—	—
Social								
Human rights policy	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Policy against child labor	No	No	No	No	No	No	No	Yes
Quality assurance and recall policy	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Consumer data protection policy	No	No	No	No	No	No	No	No
Equal opportunity policy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Gender pay gap breakout	No	No	No	No	No	No	No	No
Pct women in workforce	—	—	—	—	—	—	—	76
Pct disabled in workforce	—	—	—	—	—	—	—	1
Business ethics policy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Anti-bribery ethics policy	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Health and safety policy	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Lost time incident rate - employees	—	—	—	—	—	—	0	0
Total recordable incident rate - employees	—	—	—	—	—	—	0	1
Training policy	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Fair remuneration policy	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Number of employees – CSR	—	—	—	—	—	—	8,597	8,877
Employee turnover pct	—	—	—	—	—	—	—	43
Total hours spent by firm - employee training	—	—	—	—	—	—	—	54,702
Social supply chain management	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Governance								
Board size	10	10	10	12	12	12	12	11
No. of independent directors (ID)	4	4	4	4	4	4	4	4
No. of women on board	3	3	3	4	4	3	3	3
No. of non-executive directors on board	5	5	5	5	5	5	5	5
Company conducts board evaluations	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
No. of board meetings for the year	6	5	6	5	5	6	6	6
Board meeting attendance pct	93	94	90	96	100	99	94	97
Board duration (years)	—	—	—	—	—	—	—	—
Director share ownership guidelines	No	No	No	No	No	No	No	No
Age of the youngest director	28	29	30	29	30	31	32	33
Age of the oldest director	72	73	74	75	76	77	78	79
No. of executives / company managers	5	5	5	5	5	7	7	6
No. of female executives	1	—	—	—	—	—	—	—
Executive share ownership guidelines	No	No	No	No	No	No	No	No
Size of audit committee	3	3	3	3	3	3	3	3
No. of ID on audit committee	3	3	3	3	3	3	3	3
Audit committee meetings	4	4	5	5	5	5	5	5
Audit meeting attendance %	100	92	100	93	100	100	93	100
Size of compensation committee	0	0	0	0	0	0	0	0
No. of ID on compensation committee	—	—	—	—	—	—	—	—
No. of compensation committee meetings	—	—	—	—	—	—	—	—
Compensation meeting attendance %	—	—	—	—	—	—	—	—
Size of nomination committee	0	0	0	0	0	0	0	0
No. of nomination committee meetings	—	—	—	—	—	—	—	—
Nomination meeting attendance %	—	—	—	—	—	—	—	—
Sustainability governance								
Verification type	No	No	No	No	No	No	No	No

Sources: Bloomberg; FSSIA's compilation

Disclaimer for ESG scoring

ESG score	Methodology	Rating																				
The Dow Jones Sustainability Indices (DJSI) By S&P Global	The DJSI World applies a transparent, rules-based component selection process based on the companies' Total Sustainability Scores resulting from the annual S&P Global Corporate Sustainability Assessment (CSA). Only the top-ranked companies within each industry are selected for inclusion.	Be a member and invited to the annual S&P Global Corporate Sustainability Assessment (CSA) for DJSI. Companies with an S&P Global ESG Score of less than 45% of the S&P Global ESG Score of the highest scoring company are disqualified. The constituents of the DJSI indices are selected from the Eligible Universe.																				
SET ESG Ratings List (SETESG) by The Stock Exchange of Thailand (SET)	SET ESG quantifies responsibility in Environmental and Social issues by managing business with transparency in Governance, updated annually. Candidates must pass the preemptive criteria, with two crucial conditions: 1) no irregular trading of the board members and executives; and 2) free float of >150 shareholders, and combined holding must be >15% of paid-up capital. Some key disqualifying criteria include: 1) CG score of below 70%; 2) independent directors and free float violation; 3) executives' wrongdoing related to CG, social & environmental impacts; 4) equity in negative territory; and 5) earnings in red for > 3 years in the last 5 years.	To be eligible for SETESG inclusion , verified data must be scored at a minimum of 50% for each indicator, unless the company is a part of DJSI during the assessment year. The scoring will be fairly weighted against the nature of the relevant industry and materiality. SETESG Index is extended from the SET ESG Ratings companies whose 1) market capitalization > THB5b (~USD150b); 2) free float >20%; and 3) liquidity >0.5% of paid-up capital for at least 9 out of 12 months. The SETTHSI Index is a market capitalisation-weighted index, cap 5% quarterly weight at maximum, and no cap for number of stocks.																				
CG Score by Thai Institute of Directors Association (Thai IOD)	An indicator of CG strength in sustainable development, measured annually by the Thai IOD, with support from the Stock Exchange of Thailand (SET). The results are from the perspective of a third party, not an evaluation of operations.	Scores are rated in six categories: 5 for Excellent (90-100), 4 for Very Good (80-89), 3 for Good (70-79), 2 for Fair (60-69), 1 for Pass (60-69), and not rated for scores below 50. Weightings include: 1) the rights; 2) and equitable treatment of shareholders (weight 25% combined); 3) the role of stakeholders (25%); 4) disclosure & transparency (15%); and 5) board responsibilities (35%).																				
AGM level By Thai Investors Association (TIA) with support from the SEC	It quantifies the extent to which shareholders' rights and equitable treatment are incorporated into business operations and information is transparent and sufficiently disclosed. All form important elements of two out of five the CG components to be evaluated annually. The assessment criteria cover AGM procedures before the meeting (45%), at the meeting date (45%), and after the meeting (10%). <i>(The first assesses 1) advance circulation of sufficient information for voting; and 2) facilitating how voting rights can be exercised. The second assesses 1) the ease of attending meetings; 2) transparency and verifiability; and 3) openness for Q&A. The third involves the meeting minutes that should contain discussion issues, resolutions and voting results.)</i>	The scores are classified into four categories: 5 for Excellent (100), 4 for Very Good (90-99), 3 for Fair (80-89), and not rated for scores below 79.																				
Thai CAC By Thai Private Sector Collective Action Against Corruption (CAC)	The core elements of the Checklist include corruption risk assessment, establishment of key controls, and the monitoring and developing of policies. The Certification is good for three years. <i>(Companies deciding to become a CAC certified member start by submitting a Declaration of Intent to kick off an 18-month deadline to submit the CAC Checklist for Certification, including risk assessment, in place of policy and control, training of managers and employees, establishment of whistleblowing channels, and communication of policies to all stakeholders.)</i>	The document will be reviewed by a committee of nine professionals. A passed Checklist will move for granting certification by the CAC Council approvals whose members are twelve highly respected individuals in professionalism and ethical achievements.																				
Morningstar Sustainalytics	The Sustainalytics' ESG risk rating provides an overall company score based on an assessment of how much of a company's exposure to ESG risk is unmanaged. <i>Sources to be reviewed include corporate publications and regulatory filings, news and other media, NGO reports/websites, multi-sector information, company feedback, ESG controversies, issuer feedback on draft ESG reports, and quality & peer reviews.</i>	A company's ESG risk rating score is the sum of unmanaged risk. The more risk is unmanaged, the higher ESG risk is scored. <table><tr><th>NEGL</th><th>Low</th><th>Medium</th><th>High</th><th>Severe</th></tr><tr><td>0-10</td><td>10-20</td><td>20-30</td><td>30-40</td><td>40+</td></tr></table>	NEGL	Low	Medium	High	Severe	0-10	10-20	20-30	30-40	40+										
NEGL	Low	Medium	High	Severe																		
0-10	10-20	20-30	30-40	40+																		
ESG Book	The ESG score identifies sustainable companies that are better positioned to outperform over the long term. The methodology considers the principle of financial materiality including information that significantly helps explain future risk-adjusted performance. Materiality is applied by over-weighting features with higher materiality and rebalancing these weights on a rolling quarterly basis.	The total ESG score is calculated as a weighted sum of the features scores using materiality-based weights. The score is scaled between 0 and 100 with higher scores indicating better performance.																				
MSCI	MSCI ESG ratings aim to measure a company's management of financially relevant ESG risks and opportunities. It uses a rules-based methodology to identify industry leaders and laggards according to their exposure to ESG risks and how well they manage those risks relative to peers. <table><tr><td>AAA</td><td>8.571-10.000</td><td rowspan="3">Leader:</td><td rowspan="3">leading its industry in managing the most significant ESG risks and opportunities</td></tr><tr><td>AA</td><td>7.143-8.570</td></tr><tr><td>A</td><td>5.714-7.142</td></tr><tr><td>BBB</td><td>4.286-5.713</td><td rowspan="3">Average:</td><td rowspan="3">a mixed or unexceptional track record of managing the most significant ESG risks and opportunities relative to industry peers</td></tr><tr><td>BB</td><td>2.857-4.285</td></tr><tr><td>B</td><td>1.429-2.856</td></tr><tr><td>CCC</td><td>0.000-1.428</td><td>Laggard:</td><td>lagging its industry based on its high exposure and failure to manage significant ESG risks</td></tr></table>	AAA	8.571-10.000	Leader:	leading its industry in managing the most significant ESG risks and opportunities	AA	7.143-8.570	A	5.714-7.142	BBB	4.286-5.713	Average:	a mixed or unexceptional track record of managing the most significant ESG risks and opportunities relative to industry peers	BB	2.857-4.285	B	1.429-2.856	CCC	0.000-1.428	Laggard:	lagging its industry based on its high exposure and failure to manage significant ESG risks	
AAA	8.571-10.000	Leader:	leading its industry in managing the most significant ESG risks and opportunities																			
AA	7.143-8.570																					
A	5.714-7.142																					
BBB	4.286-5.713	Average:	a mixed or unexceptional track record of managing the most significant ESG risks and opportunities relative to industry peers																			
BB	2.857-4.285																					
B	1.429-2.856																					
CCC	0.000-1.428	Laggard:	lagging its industry based on its high exposure and failure to manage significant ESG risks																			
Moody's ESG solutions	Moody's assesses the degree to which companies take into account ESG objectives in the definition and implementation of their strategy policies. It believes that a company integrating ESG factors into its business model and relatively outperforming its peers is better positioned to mitigate risks and create sustainable value for shareholders over the medium to long term.																					
Refinitiv ESG rating	Designed to transparently and objectively measure a company's relative ESG performance, commitment and effectiveness across 10 main themes, based on publicly available and auditable data. The score ranges from 0 to 100 on relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly. <i>(Score ratings are 0 to 25 = poor; >25 to 50 = satisfactory; >50 to 75 = good; and >75 to 100 = excellent.)</i>																					
S&P Global	The S&P Global ESG Score is a relative score measuring a company's performance on and management of ESG risks, opportunities, and impacts compared to its peers within the same industry classification. The score ranges from 0 to 100.																					
Bloomberg	ESG Score	Bloomberg score evaluating the company's aggregated Environmental, Social and Governance (ESG) performance. The score is based on Bloomberg's view of ESG financial materiality. The score is a weighted generalized mean (power mean) of Pillar Scores, where the weights are determined by the pillar priority ranking. Values range from 0 to 10; 10 is the best.																				
Bloomberg	ESG Disclosure Score	Disclosure of a company's ESG used for Bloomberg ESG score. The score ranges from 0 for none to 100 for disclosure of every data point, measuring the amount of ESG data reported publicly, and not the performance on any data point.																				

[Rating](#) regarding the sustainable development of Thai listed companies, both on the SET and MAI, are publicly available on the website of the Securities and Exchange Commission of Thailand (SEC). Currently, ratings available are 1) "**CG Score**"; 2) "**AGM Level**"; 3) "**Thai CAC**"; and 4) **THSI**. The ratings are updated on an annual basis. FSSIA does not confirm nor certify the accuracy of such ratings.

Source: FSSIA's compilation

GENERAL DISCLAIMER

ANALYST(S) CERTIFICATION

Teerapol Udomvej, CFA FSS International Investment Advisory Securities Co., Ltd

The individual(s) identified above certify(ies) that (i) all views expressed in this report accurately reflect the personal view of the analyst(s) with regard to any and all of the subject securities, companies or issuers mentioned in this report; and (ii) no part of the compensation of the analyst(s) was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed herein.

This report has been prepared by FSS International Investment Advisory Securities Company Limited (FSSIA). The information herein has been obtained from sources believed to be reliable and accurate; however FSSIA makes no representation as to the accuracy and completeness of such information. Information and opinions expressed herein are subject to change without notice. FSSIA has no intention to solicit investors to buy or sell any security in this report. In addition, FSSIA does not guarantee returns nor price of the securities described in the report nor accept any liability for any loss or damage of any kind arising out of the use of such information or opinions in this report. Investors should study this report carefully in making investment decisions. All rights are reserved.

This report may not be reproduced, distributed or published by any person in any manner for any purpose without permission of FSSIA. Investment in securities has risks. Investors are advised to consider carefully before making investment decisions.

Company	Ticker	Price	Rating	Valuation & Risks
Bangkok Chain Hospital	BCH TB	THB 14.40	BUY	Downside risks to our DCF-based target price include 1) a slowdown in international patients due to economic concerns, political protests or floods; 2) regulatory risks from drug prices and medical bill controls; and 3) SSO provision expenses following a limited SSO budget.
Bangkok Dusit Medical Services	BDMS TB	THB 23.10	BUY	Downside risks to our DCF-based target price include 1) a slowdown in international patients due to economic concerns, political protests or floods; 2) regulatory risks from drug prices and medical bill controls; and 3) higher-than-expected capex and opex for CoE projects.
Bumrungrad Hospital	BH TB	THB 158.50	BUY	Downside risks to our DCF-based target price include 1) a slowdown in international patients due to economic concerns, political protests or floods; 2) regulatory risks from drug prices and medical bill controls; and 3) higher medical fee discount promotions, leading to a weaker EBITDA margin.
Chularat Hospital	CHG TB	THB 1.78	BUY	Downside risks to our DCF-based target price include 1) a slowdown in Thai patient volume due to economic concerns; 2) regulatory risks from drug price and medical bill controls; and 3) SSO provision expenses following limited budgets from the SSO.
Patangsit Healthcare Group	PHG TB	THB 13.90	BUY	Downside risks to our DCF-based target price include 1) a slowdown in Thai patient volume due to economic slowdown; 2) regulatory risks from drug price and medical bill controls; and 3) SSO provision expenses following limited budgets from the SSO.
Praram 9 Hospital	PR9 TB	THB 24.10	BUY	Downside risks to our DCF-based target price include 1) weak patient volumes following the economic slowdown; 2) regulatory risks from drug price and medical bill controls; and 3) higher-than-expected expenses from its new building.
Thonburi Healthcare Group	THG TB	THB 9.80	HOLD	Upside risks to our DCF-based target price include 1) a new Covid wave from a new variant; and 2) big-lot sales of Jin Wellbeing County units. Downside risks include 1) regulatory risks from drug prices and medical bill controls; and 2) a slowdown in international patients due to economic concerns.
Ramkhamhaeng Hospital	RAM TB	THB 18.10	BUY	Downside risks to our DCF-based target price include 1) weak patient volumes following the economic slowdown; 2) regulatory risks from drug price and medical bill controls; and 3) losses from its subsidiary companies.
Srivichaivejvivat	VIH TB	THB 7.15	BUY	Downside risks to our DCF-based target price include 1) a slowdown in Thai patient volume due to economic slowdown; 2) regulatory risks from drug price and medical bill controls; and 3) SSO provision expenses following limited budgets from the SSO.

Source: FSSIA estimates

Additional Disclosures

Target price history, stock price charts, valuation and risk details, and equity rating histories applicable to each company rated in this report is available in our most recently published reports. You can contact the analyst named on the front of this note or your representative at Finansia Syrus Securities Public Company Limited.

All share prices are as at market close on 28-Apr-2025 unless otherwise stated.

RECOMMENDATION STRUCTURE

Stock ratings

Stock ratings are based on absolute upside or downside, which we define as $(\text{target price}^* - \text{current price}) / \text{current price}$.

BUY (B). The upside is 10% or more.

HOLD (H). The upside or downside is less than 10%.

REDUCE (R). The downside is 10% or more.

Unless otherwise specified, these recommendations are set with a 12-month horizon. Thus, it is possible that future price volatility may cause a temporary mismatch between upside/downside for a stock based on market price and the formal recommendation.

* In most cases, the target price will equal the analyst's assessment of the current fair value of the stock. However, if the analyst doesn't think the market will reassess the stock over the specified time horizon due to a lack of events or catalysts, then the target price may differ from fair value. In most cases, therefore, our recommendation is an assessment of the mismatch between current market price and our assessment of current fair value.

Industry Recommendations

Overweight. The analyst expects the fundamental conditions of the sector to be positive over the next 12 months.

Neutral. The analyst expects the fundamental conditions of the sector to be maintained over the next 12 months.

Underweight. The analyst expects the fundamental conditions of the sector to be negative over the next 12 months.

Country (Strategy) Recommendations

Overweight (O). Over the next 12 months, the analyst expects the market to score positively on two or more of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Neutral (N). Over the next 12 months, the analyst expects the market to score positively on one of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Underweight (U). Over the next 12 months, the analyst does not expect the market to score positively on any of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.